Avoid common mistakes on your manuscript.
Correction to: Drugs & Therapy Perspectives https://doi.org/10.1007/s40267-018-00596-3
Paragraph 1, Sentences 1 and 2: the following text, which previously read:
“After publication in volume 34, issue 10, pages 457–465, Ipsen Pharma requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Ipsen Pharma.”
Should read:
“After publication in volume 34, issue 10, pages 457–465, Exelixis, Inc. (Alameda, CA, USA) requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Exelixis, Inc. (Alameda, CA, USA).”
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Lyseng-Williamson, K.A. Correction to: “Correction to: Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use”. Drugs Ther Perspect 35, 200 (2019). https://doi.org/10.1007/s40267-019-00613-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-019-00613-z